Cargando…

Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments

Background: Advances in cancer medicines have resulted in tangible health impacts, but the magnitude of benefits of approved cancer medicines could vary greatly. Health Technology Assessment (HTA) is a multidisciplinary process used to inform resource allocation through a systematic value assessment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trapani, Dario, Tay-Teo, Kiu, Tesch, Megan E., Roitberg, Felipe, Sengar, Manju, Altuna, Sara C., Hassett, Michael J., Genazzani, Armando A., Kesselheim, Aaron S., Curigliano, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406873/ https://www.ncbi.nlm.nih.gov/pubmed/36005193 http://dx.doi.org/10.3390/curroncol29080455

Ejemplares similares

The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region
por: Trapani, Dario, et al.
Publicado: (2020)

Master protocols in immuno-oncology: do novel drugs deserve novel designs?
por: Mazzarella, Luca, et al.
Publicado: (2020)

COVID-19 vaccines in patients with cancer
por: Trapani, Dario, et al.
Publicado: (2021)

Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021()
por: Trapani, Dario, et al.
Publicado: (2021)

Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
por: Fundytus, Adam, et al.
Publicado: (2021)

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
por: Viale, Giulia, et al.
Publicado: (2017)

Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related disease pandemic
por: Tarantino, Paolo, et al.
Publicado: (2020)

European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows
por: Passaro, Antonio, et al.
Publicado: (2020)

Cancer Medicines: What Is Essential and Affordable in India?
por: Sengar, Manju, et al.
Publicado: (2022)

Management of Cardiac Toxicity Induced by Chemotherapy
por: Trapani, Dario, et al.
Publicado: (2020)

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
por: Marra, Antonio, et al.
Publicado: (2020)

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
por: Vreman, Rick A., et al.
Publicado: (2020)

Tracking the Workforce 2020-2030: Making the Case for a Cancer Workforce Registry
por: Srivastava, Archita, et al.
Publicado: (2021)

Barriers in access to oncology drugs — a global crisis
por: Barrios, Carlos, et al.
Publicado: (2022)

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
por: Solà-Morales, Oriol, et al.
Publicado: (2019)

Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey
por: Denburg, Avram E., et al.
Publicado: (2022)

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
por: Roitberg, F., et al.
Publicado: (2023)

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
por: Valenza, Carmine, et al.
Publicado: (2023)

From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26–30th September 2014
por: Curigliano, Giuseppe
Publicado: (2014)

Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
por: Tay-Teo, Kiu, et al.
Publicado: (2019)

Editorial: Non-invasive Technology Advances in Oncology
por: Teo, Chong Boon, et al.
Publicado: (2021)

Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
por: Valenza, Carmine, et al.
Publicado: (2023)

Spirituality in the uncertainty of illness: the perspective of oncology patients
por: de Almeida, Roberto Firpo, et al.
Publicado: (2023)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

Delivery of Global Cancer Care: An International Study of Medical Oncology Workload
por: Fundytus, Adam, et al.
Publicado: (2017)

The HER2-low revolution in breast oncology: steps forward and emerging challenges
por: Nicolò, Eleonora, et al.
Publicado: (2023)

Immuno-oncology trends: preclinical models, biomarkers, and clinical development
por: Franklin, Maryland Rosenfeld, et al.
Publicado: (2022)

Measurement Uncertainties in Science and Technology
por: Grabe, Michael
Publicado: (2005)

Measurement uncertainties in science and technology
por: Grabe, Michael
Publicado: (2014)

Identification of Illness Uncertainty in Veterinary Oncology: Implications for Service
por: Stoewen, Debbie L., et al.
Publicado: (2019)

Opportunities and challenges of implementing Pharmacogenomics in cancer drug development
por: Tarantino, Paolo, et al.
Publicado: (2019)

Should I call psycho-oncology? Training nurses on psycho-oncological screening reduces uncertainties
por: Dreismann, Lara, et al.
Publicado: (2023)

Stakeholder Perspectives on Navigating Evidentiary and Decision Uncertainty in Precision Oncology
por: Pollard, Samantha, et al.
Publicado: (2022)

Expression of tumor-associated antigens in breast cancer subtypes
por: Curigliano, Giuseppe, et al.
Publicado: (2019)

Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars
por: Stebbing, Justin, et al.
Publicado: (2020)

Repurposing anticancer drugs for the management of COVID-19
por: El Bairi, Khalid, et al.
Publicado: (2020)

Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data
por: Ball, Graeme, et al.
Publicado: (2023)

Ranking negative emissions technologies under uncertainty
por: Ng, W.Y., et al.
Publicado: (2020)

Summary of the published Indian data on chronic myeloid leukemia
por: Singhal, Manish K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ug8hpgpc01ffgj1jo8a96r944t